BBL
NVO icon

Beck Bode LLC’s Novo Nordisk NVO Stock Holding History

Beck Bode LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,700
Closed -$623K – 140
2023
Q2 		$623K Buy
7,700
+770
+11% +$62.9K 0.15% 107
2023
Q1 		$551K Sell
6,930
-2,692
-28% -$191K 0.14% 114
2022
Q4 		$651K Buy
+9,622
New +$564K 0.15% 110

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Beck Bode LLC's NVO Position: Q3 2023 in Review

Beck Bode LLC sold out of Novo Nordisk (NVO) in Q3 2023, closing a stake of 7,700 shares — an estimated $623K sold.

Beck Bode LLC first reported a position in NVO in Q4 2022 and held it in 3 quarters. The position peaked at $651K in Q4 2022. 1,306 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Beck Bode LLC reported no remaining Novo Nordisk position as of Q3 2023 after selling out during the quarter.
  • Beck Bode LLC sold 7,700 Novo Nordisk shares in Q3 2023, an estimated $623K.
  • Beck Bode LLC first reported a position in Novo Nordisk in Q4 2022 and held it in 3 quarters.
  • Beck Bode LLC's Novo Nordisk position peaked at $651K in Q4 2022.
  • 1,306 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Beck Bode LLC's 13F filing for Q3 2023, filed 2 Nov 2023.